Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
KOLs to provide insight and discussion of HPN328 targeting SCLC, NEPC and other neuroendocrine tumors Abstract with HPN328 interim data accepted for poster presentation at the European Society for.
Abstracts for HPN217 and HPN328 accepted for presentations at the International Myeloma Society Annual Meeting and the European Society for Medical Oncology in the fall Enrollment for HPN328 .